Patents by Inventor Allan James Saul
Allan James Saul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240293524Abstract: The present invention is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to multiple antigens to form multi functionalized nOMV-antigen conjugated derivatives, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates are also provided.Type: ApplicationFiled: March 28, 2024Publication date: September 5, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Renzo ALFINI, Roberta Di Benedetto, Francesca Micoli, Allan James Saul
-
Patent number: 12036285Abstract: The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.Type: GrantFiled: November 23, 2017Date of Patent: July 16, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Renzo Alfini, Francesca Micoli, Allan James Saul
-
Patent number: 12005109Abstract: The present invention is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to multiple antigens to form multi functionalized nOMV-antigen conjugated derivatives, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates are also provided.Type: GrantFiled: August 8, 2018Date of Patent: June 11, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Renzo Alfini, Roberta Di Benedetto, Francesca Micoli, Allan James Saul
-
Patent number: 11986518Abstract: This invention relates to immunogenic compositions, particularly vaccine compositions, for use in providing protection against illness caused by bacterial infection with Shigella strains.Type: GrantFiled: August 5, 2020Date of Patent: May 21, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Christiane Gerke, Laura Bartle Martin, Allan James Saul
-
Publication number: 20230263877Abstract: A Shigella flexneri O-antigen of a first serotype or subserotype are provided for use in raising an immune response against one or more Shigella flexneri O-antigen of a different serotype or subserotype, together with associated binding moieties, pharmaceutical compositions, kits, uses or methods.Type: ApplicationFiled: October 15, 2020Publication date: August 24, 2023Inventors: Francesco Citiulo, Laura Bartle Martin, Allan James Saul
-
Publication number: 20230137821Abstract: The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.Type: ApplicationFiled: November 23, 2017Publication date: May 4, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Renzo ALFINI, Francesca MICOLI, Allan James SAUL
-
Publication number: 20230137914Abstract: The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-linker-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.Type: ApplicationFiled: November 23, 2017Publication date: May 4, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Roberta DI BENEDETTO, Francesca MICOLI, Allan James SAUL
-
Publication number: 20220008529Abstract: The present invention is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to multiple antigens to form multi functionalized nOMV-antigen conjugated derivatives, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates are also provided.Type: ApplicationFiled: August 8, 2018Publication date: January 13, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Renzo ALFINI, Roberta DI BENEDETTO, Francesca MICOLI, Allan James SAUL
-
Publication number: 20200384096Abstract: This invention relates to immunogenic compositions, particularly vaccine compositions, for use in providing protection against illness caused by bacterial infection with Shigella strains.Type: ApplicationFiled: August 5, 2020Publication date: December 10, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Christiane GERKE, Laura Bartle MARTIN, Allan James SAUL
-
Patent number: 10683370Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.Type: GrantFiled: May 11, 2018Date of Patent: June 16, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Allan James Saul, Francesca Micoli
-
Publication number: 20180334515Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.Type: ApplicationFiled: May 11, 2018Publication date: November 22, 2018Applicant: GlaxoSmithKline Biologicals SAInventors: Allan James SAUL, Francesca MICOLI
-
Patent number: 10113009Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.Type: GrantFiled: May 9, 2016Date of Patent: October 30, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Allan James Saul, Francesca Micoli
-
Patent number: 10098947Abstract: The invention relates to a conjugate based on Vi polysaccharide which is fragmented and a carrier protein, to compositions comprising said conjugate and to methods for making said conjugates and compositions.Type: GrantFiled: November 7, 2014Date of Patent: October 16, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Calman Alexander MacLennan, Laura Bartle Martin, Francesca Micoli, Allan James Saul
-
Publication number: 20180169206Abstract: This invention relates to immunogenic compositions, particularly vaccine compositions, for use in providing protection against illness caused by bacterial infection with Shigella strains.Type: ApplicationFiled: June 15, 2016Publication date: June 21, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Christiane GERKE, Laura Bartle MARTIN, Allan James SAUL
-
Publication number: 20160297895Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.Type: ApplicationFiled: May 9, 2016Publication date: October 13, 2016Inventors: Allan James SAUL, Francesca MICOLI
-
Publication number: 20160263213Abstract: The invention relates to a conjugate based on Vi polysaccharide which is fragmented and a carrier protein, to compositions comprising said conjugate and to methods for making said conjugates and compositions.Type: ApplicationFiled: November 7, 2014Publication date: September 15, 2016Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Calman Alexander MACLENNAN, Laura Bartle MARTIN, Francesca MICOLI, Allan James SAUL
-
Patent number: 9358284Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.Type: GrantFiled: September 14, 2012Date of Patent: June 7, 2016Assignee: GlaxoSmithKline Biologicals SAInventors: Allan James Saul, Francesca Micoli
-
Publication number: 20140329998Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.Type: ApplicationFiled: September 14, 2012Publication date: November 6, 2014Applicant: NOVARTIS AGInventors: Allan James Saul, Francesca Micoli
-
Publication number: 20130017219Abstract: A two stage size filtration process is used to purify immunogenic bacterial vesicles. A first step separates the vesicles from intact bacteria based on their different sizes, with the smaller vesicles passing into the filtrate (permeate). A second step then uses a finer filter to remove smaller contaminants, with the vesicles remaining in the retentate. This two stage process is extremely simple to operate but has been shown to give vesicles of high purity.Type: ApplicationFiled: September 28, 2010Publication date: January 17, 2013Applicant: NOVARTIS VACCINES INSTITUTE FOR GLOBAL HEALTH SRLInventors: Vito Di Cioccio, Anna Maria Colucci, Allan James Saul
-
Patent number: 6174528Abstract: The present invention relates generally to chimeric peptides comprising one or more protective epitopes in a conformation enabling inmunological interactivity and to vaccine compositions comprising same. The present invention is particularly directed to a chimeric peptide capable of inducing protecting antibodies against Group A streptococci.Type: GrantFiled: July 31, 1997Date of Patent: January 16, 2001Assignees: Counsel of the Queensland Institute of Medical Research, Commonwealth Scientific and Industrial Research Organisation, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research of Royal Melbourne Hospital, Biotech Australia PTY Limited, CSL LimitedInventors: Juan Anton Cooper, Wendy Anne Relf, Michael Francis Good, Allan James Saul